TABLE 1.

Correlation of NNMT expression and prognosis in gastric cancer with various clinicopathological factors.

Clinicopathological characteristics	Overall survival (n = 876)			Progression-free survival (n = 641)
	n	Hazard ratio	p	n	Hazard ratio	p
SEX
Female	236	1.47 (1.04−2.09)	0.029	201	1.58 (1.02−2.45)	0.041
Male	545	1.46 (1.16−1.83)	0.00099	438	1.37 (1.08−1.74)	0.0096
STAGE
I	67	0.34 (0.12−0.98)	0.072	60	0.37 (0.11−1.22)	0.088
II	140	2.36 (1.09−5.11)	0.024	131	1.93 (1.06−3.52)	0.029
III	305	1.53 (1.15−2.03)	0.0035	186	1.84 (1.24−2.74)	0.0022
IV	148	2.00 (1.34−2.97)	0.00049	141	1.66 (1.11−2.44)	0.01
STAGE T
2	241	2.05 (1.32−3.18)	0.001	239	1.97 (1.30−2.99)	0.0012
3	204	1.59 (1.12−2.27)	0.0089	204	1.31 (0.93−1.85)	0.12
4	38	1.90 (0.80−4.50)	0.14	39	2.50 (1.07−5.83)	0.029
STAGE N
0	74	1.49 (0.64−3.45)	0.35	72	1.57 (0.68−3.63)	0.29
1	225	2.51 (1.65−3.84)	9.8e−06	222	2.28 (1.54−3.38)	2.3e−05
2	121	2.35 (1.44−3.82)	0.00041	125	2.28 (1.43−3.63)	0.00037
3	76	1.99 (1.16−3.42)	0.011	76	1.98 (1.16−3.38)	0.01
1 + 2 + 3	422	2.40 (1.82−3.16)	1.6e−10	423	2.16 (1.65−2.82)	7.1e−09
STAGE M
0	444	1.96 (1.48−2.59)	1.3e−06	443	1.88 (1.44−2.45)	2.3e−06
1	56	2.46 (1.33−4.55)	0.0033	56	1.59 (0.86−2.94)	0.13
LUREN CLASSIFICATION
Intestinal	320	2.69 (1.82−3.98)	2.1e−07	263	2.13 (1.49−3.05)	2.2e−05
Diffuse	241	1.82 (1.29−2.55)	0.00051	231	1.83 (1.29−2.58)	0.00057
Treatment
Surgery alone	380	1.45 (1.09−1.94)	0.011	375	1.46 (1.10−1.93)	0.0085
5-FU-based adjuvant	153	0.55 (0.38−0.78)	0.00075	153	0.62 (0.43−0.90)	0.012
Other adjuvants	76	3.83 (1.58−9.27)	0.0013	80	4.10 (1.86−9.03)	0.00015
HER2 status
negative	532	1.44 (1.15−1.80)	0.0015	408	1.47 (1.13−1.92)	0.0038
positive	344	1.40 (1.06−1.85)	0.016	233	1.42 (1.01−2.00)	0.044
HER2 status (5-FU-based adjuvant)
HER2-negative	75	0.41 (0.23−0.71)	0.001	75	0.50 (0.28−0.88)	0.014
HER2-positive	78	0.64 (0.39−1.04)	0.07	78	0.71 (0.43−1.17)	0.18

Data are from the probe 202238_s_at (NNMT), (p < 0.05) is in boldface.